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A number of studies have observed increased can-
cer incidence rates among individuals who have re-
ceived renal transplants. Generally, however, these
studies have been limited by relatively small sample
sizes, short follow-up intervals or focused on only one
cancer site. We conducted a nationwide population-
based study of 11,155 patients who underwent kidney
transplantation between 1981 and 1998. Incident can-
cers were identified up to December 31, 1999, through
record linkage to the Canadian Cancer Registry. Pat-
terns of cancer incidence in the cohort were compared
to the Canadian general population using standard-
ized incidence ratios (SIRs). We examined variations
in risk according time since transplantation, year of
transplantation and age at transplantation. In our pa-
tient population, we observed a total of 778 incident
cancers versus 313.2 expected (SIR = 2.5, 95% CI =
2.3–2.7). Site-specific SIRs were highest for cancer of
the lip (SIR = 31.3, 95% CI = 23.5–40.8), non-Hodgkin’s
lymphoma (NHL) (SIR = 8.8, 95% CI = 7.4–10.5), and
kidney cancer (SIR = 7.3, 95% CI = 5.7–9.2). SIRs for
NHL and cancer of the lip and kidney were highest and
among transplant patients. This study confirms previ-
ous findings of increased risks of posttransplant can-
cer. Our findings underscore the need for increased vig-
ilance among kidney transplant recipients for cancers
at sites where there are no population-based screening
programs in place.
Abbreviations: CCR, Canadian Cancer Registry; C.I.,
Confidence Interval; CMDB, Canadian Mortality Data-
base; CORR, Canadian Organ Replacement Registry;
ESRD, End-Stage Renal Disease; NHL, non-Hodgkin’s
Lymphoma; SIR, Standardized Incidence Ratio.
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Introduction
The prevalence of end-stage renal disease (ESRD) has risen
dramatically in Canada over the past two decades (1,2).
This has been accompanied by a concomitant increase of
renal transplantation (3), the preferred treatment modality.
Compared to dialysis, transplantation has been shown to
improve both survival and quality of life (4,5). Nonetheless,
transplantation is associated with increased risks for sev-
eral adverse health events including cancer. In particular,
the use of immunosuppressive drugs, essential for pre-
venting organ rejection in transplant recipients has been
implicated in the development of cancer (6,7).
While several epidemiologic studies have consistently
found increased cancer incidence rates among transplant
recipients (8–19), most are subject to several important lim-
itations. Many have been based on a single or small num-
ber of centers and therefore it is difficult to describe cancer
incidence rates in the reference population that gave rise
to the cases. The use of general population rates in such
studies may also be biased as the center’s referral patterns,
or systematic differences in sociodemographic character-
istics between the center and the reference population,
may lead to noncomparability. In recent years, a number of
registry-based studies have provided important insights on
cancer risk in kidney transplant recipients (8,13,17,20,21).
While such studies have made use of national cancer reg-
istries, for the most part, the number of patients has been
relatively small with limited follow-up. Therefore, they have
had limited ability to examine the long-term probability of
developing cancer and limited statistical power to charac-
terize risks for rarer forms of cancer. The largest study con-
ducted to date, consisted of 13,077 patients with 110,395
persons years of follow-up who received a kidney trans-
plant in Australia or New Zealand between 1980 and 2003
(20); a more detailed analyses of a subset of these patients
has recently been published (22). Our cohort shares many
common features with their patient population including: a
population-based design, lengthy follow-up interval and a
relatively large sample size.
In this investigation, we report on patterns of cancer in-
cidence among 11,155 individuals who received a renal
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transplant between 1981 and 1998 using a national Cana-
dian organ transplantation registry. This represents one of
the largest cohorts of renal transplant patients assembled
to date, with follow-up for some subjects extending up to
19 years. These features permitted us to characterize can-
cer risk according to the time since transplantation, age at
transplantation and calendar period.
Material and Methods
Study population
The cohort was constructed with transplant recipients identified by using
the Canadian Organ Replacement Register database (CORR). This database
is a national organ failure registry that contains information for patients
who initiated renal replacement therapy (RRT) in Canada from January 1,
1981. Patients who were on RRT prior to January 1, 1981, were not regis-
tered and thus even though they may have received a transplant after 1981,
they are not included in this analysis. The cohort used for this analysis was
comprised of all patients who initiated RRT from January 1981, to Decem-
ber 31, 1998, and who received a first kidney transplant during that time.
These data were provided to CORR by all 27 kidney transplant programs
in Canada. The data collected included: date of birth, sex, province of resi-
dence, race/ethnicity, primary kidney disease, and since 1988 a number of
co-morbid medical conditions present at the time of RRT, and initial RRT
modality. The renal programs report on an annual basis changes in dialy-
sis modality, new kidney transplants, kidney transplant failures and deaths.
Comparisons between data submitted from hospitals, and provincial Or-
gan Procurement Organizations provide an indication of the completeness
of the CORR database. Analyses of these data suggest that there is min-
imal (<4%) underreporting of kidney transplants within CORR (23). In ad-
dition, CORR performs active follow-up surveillance of these patients and
approximately 1% of these patients have been lost to follow-up. A more
detailed description of the CORR registry has been published elsewhere
(23,24).
Initially, we identified a total of 11,391 individuals who had received a re-
nal transplant between 1981 and 1998. From this patient population, we
excluded 233 patients who were diagnosed with cancer (excluding non-
melanoma skin cancer) before transplantation. Patients were followed from
the date of the first recorded renal transplant. Three individuals were ex-
cluded as we were unable to determine their sex. There were a total of
11,155 patients that remained. Consistent with previous analyses we also
excluded follow-up interval within the first 30 days after transplant (8). A
total of 122 patients died or were diagnosed with cancer during this period.
Therefore, our risk estimates are based on 11,033 patients.
Ascertainment of health outcomes
The mortality experience of the cohort was determined by linking the cohort
to the Canadian Mortality database using a probabilistic procedure referred
to as the generalized record linkage system (GRLS). GRLS compares com-
mon fields in the two files to be linked, assigns weights to the resulting
links and calculates a total weight. Links with a sufficiently high weight are
accepted as a match. The Canadian Mortality Database (CMDB) maintained
by Statistics Canada, contains death data for all Canadian residents from
1950 onwards. It is possible that some deaths may have been missed be-
cause patients died outside the country. For out of country deaths, only
those that occur in the United States are reported, and Canada currently
receives abstracted death data from approximately 20 states (25). Previ-
ous research suggests that the number of deaths that would be missed
would be quite small given the personal identifying information available
for this cohort (26,27). Both these studies found that the probability of
correctly identifying deceased and alive subjects from record linkage to
the CMDB was 98% and close to 100%, respectively. While mortality out-
comes were not the focus of our investigation, date of death information
was used to determine the last day of follow so that the person–years could
be determined accurately. Where no death link was found, we assumed
that the person was alive at the end of the study interval (December 31,
1999).
In Canada, each province and territory has a Cancer Act and a legislated
responsibility for cancer collection and control, and therefore the reporting
of primary malignant cancers is in theory complete. Incidence data supplied
by the cancer registries are compiled into the Canadian Cancer Registry
(CCR) (28), which is maintained by the Health Statistics Division at Statis-
tics Canada. The CCR is a patient-based system that contains information
on all Canadian residents, dead or alive, who have been diagnosed with can-
cer, excluding squamous and basal cell skin cancer. It has been estimated
that the CCR captures at least 95% of all incident cancer cases in Canada
(29). For the purposes of these analyses, incident cases of cancer diag-
nosed between 1969 and 1999 were identified through record linkage of
the personal identifying information contained in the CORR patient records
to the CCR. We linked the cohort to cancer incidence data before transplan-
tation to exclude from analysis those individuals previously diagnosed with
cancer. As with the mortality linkage, patients for whom no link to the CCR
was found, were assumed to be cancer-free at the last date of follow-up
(i.e. date of death or December 31, 1999).
Probabilistic record linkage was done using personal identifying information
that included surname, surname at birth, given names, birth date, social
insurance numbers and place of residence. Unfortunately, there has been
no evaluation of the accuracy of ascertaining incident cancers by linking data
to the CCR. However, given the high quality and completeness in the CCR,
and the similarity in record linkage methodology used, it is reasonable to
assume that record linkage to the CCR will be at least as accurate as record
linkage to the CMDB. Nonetheless, it is important to note that some incident
cases may have been missed by an inability to identify cases that might
have occurred among patients who moved outside of Canada. However, as
mentioned previously, it has been estimated that fewer than 5% of cancers
would be missed, and therefore, the overall bias on our presented SIRs
should be minimal.
Statistical analysis
To exclude cases of cancer prevalent at the time of transplantation, we
adopted the same methodology as Adami et al. (8) and excluded the 30-
day period immediately after transplantation from our follow-up. Follow-up
extended until the earliest of: (i) date of cancer diagnosis, (ii) date of death
or (iii) December 31, 1999. The DATAB module in the Epicure software
program was used to tabulate these person–years (30).
Person–years of follow-up and incident cases of cancer were tabulated
across strata defined by: attained age (18–24, 25–29, 30–34,. . . , 75–79,
≥80), calendar period of follow-up (1981–1984, 1985–1988, 1989–1993,
1994–1996, 1997–1999), year of transplantation (1981–1984, 1985–1988,
1989–1993, 1994–1998), age at transplantation (<35, 35–44 and ≥45), sex
(male, female), and time since transplantation (>30 days to <1 year, 1 to <5,
5 to <10, ≥10 years). Attained age, calendar period and time since surgery
were time-dependent variables as their values changed over follow-up.
Cancer risk was evaluated by using the method of indirect standardization
to calculate the standardized incidence ratio (SIR), which is the ratio of the
observed-to-expected number of incident cancers. The 95% confidence in-
tervals were calculated by assuming that the observed cancers followed a
Poisson distribution using formulae detailed elsewhere (31). Stratified anal-
yses were conducted to examine variations in the SIR across categories of
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the age at transplantation, sex, length of follow-up and year of transplanta-
tion.
Finally, we applied competing risk survival analysis methods to estimate
the cumulative incidence of developing certain cancers by time since trans-
plantation. This method allows for the fact that persons who die or develop
another form of cancer are no longer at risk of developing the index cancer.
This differs from the standard cumulative incidence estimated by the Ka-
plan Meier, which would introduce bias as it assumes that those who die
remain at risk in the future (32). Our estimates of cumulative incidence are
based on formulae presented by Gooley et al. (33).
Results
Between January 1, 1981 and December 31, 1998, a to-
tal of 11,391 kidney transplants among patients initiating
RRT during that period were identified from the CORR
database. After excluding individuals who were diagnosed
with cancer prior to transplantation, as well as those for
whom sex could not be ascertained, our analysis file
consisted of 11,155 subjects who had accrued 81,237
person–years of follow-up. A larger proportion of renal
transplantations were performed in males (63.2%) than in
their female counterparts (Table 1). Nearly half of all trans-
plants occurred among individuals between the ages of
30 and 50. Of note, 12.4% of all transplantations occurred
before cyclosporine was widely used in transplantation
surgeries (1985).
Patterns of cancer incidence among renal transplant pa-
tients were compared to the Canadian population (Table 2).
Overall, after applying age–sex and calendar-specific inci-
dence rates to the tabulated person–years of follow-up, the
risk of cancer among transplant recipients was 2.5 times
Table 1: Characteristics of 11,155 patients∗ who received a renal trans-
plant, Canadian Organ Replacement Registry, 1981 and 1998
Number Person–years
Characteristic of patients Percentage of follow-up† Percentage
Age at surgery (in years)
<10 295 2.6 2450.9 3.0
10 < 20 696 6.2 6266.8 7.7
20 < 30 1697 15.2 15,377.8 18.9
30 < 40 2568 23.0 19,892.4 24.5
40 < 50 2581 23.1 18,131.5 22.3
50 < 60 2105 18.9 13,167.5 16.2
60 < 70 1072 9.6 5320.3 6.5
≥70 141 1.3 630.1 0.8
Sex
Male 7055 63.2 50,604.0 62.3
Female 4100 36.8 30,633.3 37.7
Year of surgery
1981–1984 1387 12.4 16,993.3 20.9
1985–1988 2642 23.7 26,460.4 32.6
1989–1993 3646 32.7 25,843.4 31.8
1993–1998 3480 31.2 11,940.2 14.7
Total 11,155 100.0 81,237.3 100.0
∗Based on characteristics of patients at the time of their first transplant
and excludes those individuals who had a previous diagnosis of cancer
(excluding nonmelanoma skin cancer) at the time of transplantation.
†Person–years of follow-up calculated from 30 days after transplantation
until the earliest of death, cancer diagnosis or December 31, 1999.
higher (95% C.I. = 2.3–2.7) than the general Canadian pop-
ulation. SIRs were highest for cancer of the lip (SIR = 31.3),
non-Hodgkin’s lymphoma (SIR = 8.8), and kidney cancer
(SIR = 7.3). Greater than twofold excesses that were sta-
tistically significant were also noted for the following can-
cer sites: head and neck, stomach, bladder, leukemia, gall-
bladder, larynx, lung, connective tissue, Hodgkin’s disease,
vulva, multiple myeloma and thyroid. There were no site-
specific cancer SIRs that were less than unity.
In Table 3, we present findings from our stratified SIR anal-
ysis by: time since transplantation, year of transplantation,
sex and age at transplantation. The SIRs were inversely
related to age at transplantation for all cancers, NHL, lip
and kidney cancer. For NHL, the SIR was highest in the
30–<365 day posttransplant time interval (SIR = 27.2), but
remained significantly increased for the 1–<5, 5–<10 and
≥10 year posttransplant intervals. For kidney cancer, the
decrease in the SIR (i.e. as follow-up time increased) was
much less pronounced; the same was observed for all can-
cer sites (combined). Interestingly, for lip cancer, the small-
est SIR occurred in the 30–365 posttransplant interval. For
each of NHL, lip cancer, kidney cancer and all sites com-
bined, the SIR was significantly increased even in the ≥10
year posttransplant interval. For NHL, the SIRS were high-
est in more recent calendar periods. SIRs were generally
higher among males.
The cumulative incidence of cancer and death among re-
nal transplant patients, by time since transplantation, is
presented in Figure 1. After 17 years of follow-up, the
cumulative incidence of cancer and death among the trans-
plantation patients was approximately 12% and 38%, re-
spectively. The cumulative incidence estimates for other
cancer sites for which high SIRs were observed (non-
Hodgkin’s lymphoma, kidney cancer, cancer of the lip) are
illustrated in Figure 2. As described earlier, these estimates
are adjusted for the competing risks of death and diag-
noses for other cancers.
Discussion
This investigation provides additional information about the
long-term risk of developing cancer following kidney trans-
plantation. The study features a nationwide population-
based sample of over 11,000 kidney transplant patients
who were followed for up to 19 years. The size of this co-
hort is slightly less than the patient population of 13,077
in Australia and New Zealand (20), and nearly double that
of the next largest cohort for which similar data have been
published (8). Increased sample size and length of follow-
up lead to more precise SIR estimates and an opportu-
nity to examine less prevalent forms of cancer (e.g. oral).
We explicitly estimate the SIR by time since transplanta-
tion, which allowed us to characterize separate the short-
and long-term risks of developing cancer among transplant
recipients.
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Table 2: Standardized incidence ratios (SIRs)∗ for selected cancers among patients undergoing renal transplantation between 1981 and
1998, Canadian Organ Replacement Registry
Cancer Observed Expected
site ICD-9 cases cases SIR 95% C.I.
All cancers 778 313.3 2.5 (2.3, 2.7)
Oral 140–149 81 10.5 7.7 (6.1, 9.6)
Lip 140 54 1.7 31.3 (23.5, 40.8)
Head and neck 141–149 27 8.8 3.1 (2.0, 4.5)
Esophagus 150 5 3.2 1.5 (0.5, 3.6)
Stomach 151 15 7.2 2.1 (1.2, 3.4)
Colorectal 153–154 51 37.8 1.4 (1.0, 1.8)
Liver 155 5 2.7 1.8 (0.6, 4.3)
Gallbladder 156 7 1.7 4.1 (1.7, 8.5)
Pancreas 157 7 6.5 1.1 (0.4, 2.2)
Larynx 161 8 4.6 1.7 (0.7, 3.4)
Lung 162 108 51.5 2.1 (1.7, 2.5)
Connective tissue 171 10 2.1 4.8 (2.3, 8.8)
Malignant melanoma 172 20 10.5 1.9 (1.2, 3.0)
Bladder 188 24 12.1 2.0 (1.3, 3.0)
Kidney 189 71 9.7 7.3 (5.7, 9.2)
Nervous system 191,192 8 6.4 1.3 (0.5, 2.5)
Thyroid 193 23 4.6 5.0 (3.1, 7.4)
Non-Hodgkin’s lymphoma 200,202 125 14.1 8.8 (7.4, 10.5)
Hodgkin’s disease 201 9 2.5 3.6 (1.7, 6.9)
Multiple myeloma 203 13 3.4 3.9 (2.1, 6.6)
Leukemia 204–208 17 7.5 2.3 (1.3, 3.6)
Male cancers
Prostate 185 37 40.5 0.9 (0.6, 1.3)
Female cancers
Breast 174 52 39.6 1.3 (1.0, 1.7)
Uterus 179,182 6 6.7 0.9 (0.3, 2.0)
Cervix 180 6 3.9 1.6 (0.6, 3.4)
Ovary 183 7 4.7 1.5 (0.6, 3.0)
Vulva 184.1–184.4 3 0.5 5.5 (1.1, 16.0)
∗Individuals were followed up from 30 days after the date of their first renal transplant until the earliest date associated with diagnosis
of an incident cancer, death or December 31, 1999.
Overall, we found that renal transplant patients had can-
cer incidence rates that were two and a half times higher
than rates observed in the Canadian population. As pre-
viously mentioned, other studies of kidney transplant pa-
tients have reported SIR estimates. The lower SIR found in
our study is due in part from our exclusion of nonmelanoma
skin cancers. Excesses of these cancers, including Kaposi’s
sarcoma have been widely reported among transplant pa-
tients (8,34,35). Indeed, the removal of nonmelanoma skin
cancers in the Swedish cohort yields an SIR of 2.5 (95%
CI = 2.2, 2.7), an estimate identical to our own. Unfor-
tunately, we were unable to examine nonmelanoma skin
cancers in our cohort as Canadian cancer registries do not
consistently record nonmelanoma skin cancers. Registra-
tion is difficult because these cancers occur relatively fre-
quently, and they are often treated successfully without
requiring hospitalization. As a result, when comparing to
the general population rates it would be difficult to delin-
eate between excesses in nonmelanoma skin cancer rates
in our transplant patients that would be attributable to treat-
ment verses excesses due to increased surveillance of this
patient population.
While consistency in SIRs across study populations is
a useful means to identify cancer sites for which there
is an excess, the interpretation of SIRs between study
populations should be done cautiously. The estimation
of the SIR is based on the age and sex distribution of
the cohort under study, and therefore, even if the same
population-based external rates are used, comparing SIRs
between populations amounts to comparing risk mea-
sures that have different standards (36). Indeed, compar-
isons of SIRS between groups in the same cohort should
also be interpreted cautiously if these groups have dif-
ferent age distributions. There were differences in the
age distribution among kidney transplant patients between
cohorts. For example, our cohort was comprised of a
greater proportions of subjects who were <40 years old
(50%) than the Swedish cohort (38%) (8) and the Aus-
tralian and New Zealand cohort (22). While the bias that
may result from comparing SIRs between study popu-
lations has led some to advocate making comparisons
using the ratio two directly standardized rates, differ-
ences between the two methods are usually negligible
(37).
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Table 3: Standardized incidence ratios (SIRs) for selected cancer sites among those who received a kidney transplant, according by age
at surgery, period of surgery, follow-up interval and sex
All cancers Non-Hodgkin’s lymphoma Lip cancer Kidney cancer
Characteristic O E SIR and 95% C O E SIR and 95% CI O E SIR and 95% CI O E SIR and 95% CI
Follow-up interval
30 d < 1 year 103 34.7 3.0 (2.4, 3.6) 46 1.6 27.2 (19.7, 36.6) 3 0.2 13.2 (2.6, 38.4) 9 1.1 8.2 (3.8, 15.6)
1 < 5 years 312 130.4 2.4 (2.1, 2.7) 34 5.9 5.8 (4.0, 8.1) 18 0.8 23.3 (13.8, 36.9) 31 4.1 7.6 (5.2, 10.8)
5 < 10 years 268 102.8 2.6 (2.3, 2.9) 33 4.6 7.2 (4.9, 10.1) 26 0.5 49.4 (32.2, 72.3) 22 3.2 7.0 (4.4, 10.5)
≥10 years 95 45.4 2.1 (1.7, 2.6) 12 2.1 5.8 (3.0, 10.1) 7 0.2 35.3 (14.1, 72.7) 9 1.4 6.5 (3.0, 12.3)
Transplantation date
1981–1984 127 51.2 2.5 (2.1, 3.0) 10 2.4 4.2 (2.0, 7.7) 13 0.3 37.5 (19.9, 64.1) 11 1.6 6.9 (3.5, 12.3)
1985–1988 227 104.7 2.2 (1.9, 2.5) 39 4.6 8.5 (6.0, 11.6) 17 0.6 27.7 (16.1, 44.3) 16 3.2 4.9 (2.8, 8.0)
1989–1993 285 109.7 2.6 (2.3, 2.9) 46 4.9 9.4 (6.9, 12.6) 21 0.6 37.6 (23.3, 57.5) 26 3.4 7.7 (5.1, 11.3)
1994–1998 139 47.7 2.9 (2.4, 3.4) 30 2.3 8.9 (5.4, 13.7) 3 0.2 14.4 (2.9, 42.0) 18 1.5 11.9 (7.0, 18.8)
Sex
Males 519 201.1 2.6 (2.4,2.8) 83 10.0 8.3 (6.6, 10.3) 43 1.6 27.1 (19.6, 36.5) 48 7.4 6.5 (4.8, 8.6)
Females 259 112.2 2.3 (2.0,2.6) 42 4.2 10.1 (7.3, 13.6) 11 0.1 77.9 (38.8, 139.2 23 2.3 10.0 (6.3, 15.0)
Age at transplantation
<30 106 12.5 8.5 (6.9, 10.3) 42 1.0 41.9 (30.2, 56.6) 7 0.1 130.1 (52.1, 268.1) 10 0.3 40.0 (19.1, 73.6
30 < 45 191 57.4 3.3 (2.9, 3.8) 35 3.6 9.7 (6.7, 13.4) 18 0.3 56.3 33.4, 89.0) 22 2.0 10.9 (6.8, 16.4)
45 < 60 315 145.1 2.2 (1.9, 2.4) 34 6.2 5.5 (3.8, 7.6) 23 0.8 28.6 (18.1, 42.9) 28 4.8 5.9 (3.9, 8.5)
≥60 166 98.4 1.7 (1.4, 2.0) 14 3.3 4.3 (2.3, 7.1) 6 0.6 10.9 (4.0, 23.7) 11 2.7 4.1 (2.1, 7.4)
Total 778 313.3 2.5 (2.3, 2.7) 125 14.1 8.8 (7.4, 10.5) 54 1.7 31.3 (23.5, 40.8) 71 9.7 7.3 (5.7, 9.2)
O = Observed number of incidence cancer cases; E = Expected number of incidence cancer cases based on age-sex-calendar specific
rates for Canada.
Few studies have reported cancer risk by posttransplant
time interval. Although Adami et al. (8) reported risk esti-
mates by time since transplant, such estimates pertained
to comparisons within the transplant population where the
period 30 days to <1 year formed the referent category.
They found a higher risk of NHL among patients during the
first year posttransplant, while no statistically significant
differences were found for all cancer sites (combined), lip
cancer and nonmelanoma skin cancer. The use of internal
cohort comparisons to examine variations in risk by time
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Figure 1: Cumulative incidence of
death and cancer among renal
transplant patients, by time since
transplantation.
cers may have been present at the time of transplanta-
tion. Detection of these cancers posttransplantation may
be due to increased surveillance. While Adami and col-
leagues did not include incident cancers that were iden-
tified during the 30 days that followed transplantation,
the definition of a suitable follow-up interval so as to
exclude cancers present at the time of transplantation
is not straightforward. As a result, comparisons of can-
cer risk by time since transplantation may be biased
as individuals with preexisting cancer at the time of
transplantation would be included in the referent group.
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Figure 2: Cumulative incidence of
all cancers, lip cancer, NHL and kid-
ney cancer, by time since trans-
plantation.
Stratified analysis, by time since transplantation using
the SIR method, provides an alternative to charactering
cancer risk by length of follow-up. Our analysis along
these lines revealed that even during the 10+ year post-
transplant interval, incidence was significantly increased
for kidney cancer (SIR = 6.5), NHL (5.8) and lip cancer
(SIR = 35.3), while a twofold increase was observed for
all cancer sites combined (SIR = 2.1). Recently, Vadjic
et al. (22) reported the highest SIRs occurring among kid-
ney transplant patients after 10 years of follow-up. Unfortu-
nately, no cancer site-specific data were presented in their
paper.
Our findings by year of transplantation provide some
clues about the effects of immunosuppression on can-
cer risk. Cyclosporine, which has been widely used since
the mid-1980s when it was substituted for azathioprine,
though many centers used triple therapy with Pred-
nisone, Cyclosporin and Azathoprine, which has been
associated with an increase in the incidence of malig-
nant lymphoma, Kaposi’s sarcoma and renal cancer (38).
While immunosuppressive treatment data were not avail-
able on an individual level in our cohort, we did find in-
creased SIRs for NHL and kidney cancer in the more
recent time periods. This corresponds to the time that
cyclosporine was more widely used to control organ re-
jection among kidney transplant recipients. Tacrolimus
and Mycophenolate mofetil were not used in Canada
to any extent until early to mid 1990s and so would
have little impact on patterns of cancer incidence in our
cohort.
Higher SIRs were observed among younger transplant pa-
tients for each of four cancer sites examined (lip, NHL,
kidney and all cancers). This result is consistent with the
findings in the Swedish cohort (8). This higher excess is
due to much smaller background incidence rates observed
among younger individuals.
In the present study, losses to follow-up were minimized
with respect to residential mobility by linking the cohort
to national cancer incidence data collected by all provincial
registries, and to the Canadian Mortality Database. As de-
scribed in detail earlier, cancer registration in Canada is near
complete (>95%) through the cooperation of the provincial
cancer registries, and the reporting of deaths is manda-
tory; therefore, few such events occurring in Canada would
have been missed. The ability to link the cohort to these
databases was excellent, given the detailed personal iden-
tifying information available. Given the reliance of cohort
members on medical services in Canada, few individuals
would be expected to have moved outside the country,
and therefore, our observed number of incident cases is
unlikely to be unduly affected from underascertainment
due to residential mobility.
The clinical practice guidelines committee of the American
Society of Transplantation has published a comprehensive
set of guidelines for outpatient renal transplant follow-up
(39). These guidelines outline in detail the recommended
approach for the prevention of disease and complications
from renal transplantation, including cancer surveillance.
We strongly recommend that all kidney transplant pro-
grams have educational programs on the early detection
of cancer for their transplant recipients. Ideally such in-
formation would be delivered during the transplant work
up process, with reinforcement on a regular and recurring
basis during posttransplant follow-up. Continuing medical
education programs about cancer awareness are also ad-
vocated for not only transplant MDs, and nurses working in
transplant clinics, but also primary care physicians that con-
tinue to see these patients on a regular basis. The particular
focus of these educational efforts should be on first, the
importance of applying meticulously the guidelines for can-
cer screening applicable to the general population. In addi-
tion those cancers, which typically occur at a much younger
age among transplant recipients and for which there are no
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recommended screening programs should be highlighted.
The high SIRs observed among those who received a kid-
ney transplant before the age of 30 underscore the need
for surveillance in this group. In this patient population,
the overall cancer SIR population was 8.5, and marked ex-
cesses in risk for cancers of the lip (SIR = 130.1), NHL
(SIR = 41.9) and kidney cancer (SIR = 40.0) warrant partic-
ular concern.
In summary, our investigation provides detailed evidence
on the increase in cancer risk faced by kidney transplant
recipients for multiple cancer sites. Comparisons between
cohort studies need to take into account the age of the
transplant recipients, length of follow-up and differences
in immunosuppressive regimens. Further analyses will aim
to characterize the effects of dialysis on the presentation of
cancer in this cohort. While organ transplantation remains
the treatment of choice for patients with ESRD, enhanced
surveillance and continued vigilance is clearly important
among transplant patients.
Acknowledgments
We thank the Occupational and Environmental Health Research Section of
Statistics Canada for linking the data to the national cancer incidence and
vital statistics registries, and to Dores Zuccarini for her insights. We also
thank the Canadian Organ Replacement Registry of the Canadian Institute
of Health Information (CIHI) for the use of their data. CORR is fully supported
from funds provided by the Federal, Provincial and Territorial Ministries of
Health. CORR would not exist without the voluntary participation of the
Canadian Society of Nephrology, the Canadian Society of Transplantation,
and the Canadian Association of Nephrology Nurses and Technicians along
with their constituent members at dialysis and transplant centers across the
country. The Kidney Foundation of Canada also supports CORR by active
participation on the board of directors and with financial support for the
publication of annual reports.
References
1. Schaubel DE, Morrison HI, Desmeules M, Parsons DA, Fenton
SS. End-stage renal disease in Canada: Prevalence projections to
2005. CMAJ 1999; 160: 1557–1563.
2. Chauhan T. End-stage renal disease patients up nearly 19%. Cmaj
2004;170:1087.
3. Parsons DA, Tracy SE, Handa KA, Greig PD. An update of the
Canadian Organ Replacement Register (1998). Clin Transpl 1998;
97–106.
4. Laupacis A, Keown P, Pus N et al. A study of the quality of life
and cost-utility of renal transplantation. Kidney Int 1996; 50: 235–
242.
5. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all
patients on dialysis, patients on dialysis awaiting transplantation,
and recipients of a first cadaveric transplant. N Engl J Med 1999;
341: 1725–1730.
6. Hampton T. Skin cancer’s ranks rise: Immunosuppression to
blame. JAMA 2005; 294: 1476–1480.
7. Sheil AG, Disney AP, Mathew TH, Amiss N. De novo malignancy
emerges as a major cause of morbidity and late failure in renal
transplantation. Transplant Proc 1993; 25: 1383–1384.
8. Adami J, Gabel H, Lindelof B et al. Cancer risk following organ
transplantation: A nationwide cohort study in Sweden. Br J Cancer
2003; 89: 1221–1227.
9. Brunner FP, Landais P, Selwood NH. Malignancies after renal
transplantation: The EDTA-ERA registry experience. European
Dialysis and Transplantation Association-European Renal Associ-
ation. Nephrol Dial Transplant 1995;10(Suppl 1):74–80.
10. Kantor AF, Hoover RN, Kinlen LJ, McMullan MR, Fraumenti JF Jr.
Cancer in patients receiving long-term dialysis treatment. Am J
Epidemiol 1987; 126: 370–376.
11. Kyllonen L, Salmela K, Pukkala E. Cancer incidence in a kidney-
transplanted population. Transpl Int 2000;13(Suppl 1):S394–
398.
12. Pond F, Serpell JW, Webster A. Thyroid cancer in the renal trans-
plant population: Epidemiological study. ANZ J Surg 2005; 75:
106–109.
13. Hoshida Y, Tsukuma H, Yasunaga Y et al. Cancer risk after
renal transplantation in Japan. Int J Cancer 1997; 71: 517–
520.
14. Chapman J, Webster AC. Cancer Report: ANZDATA Registry 2004
report. Adelaide, Australia: Australia and New Zealand Dialysis and
Transplant Registry; 2004.
15. Hoover R, Fraumeni JF Jr. Risk of cancer in renal-transplant recip-
ients. Lancet 1973; 2: 55–57.
16. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-
Australasian study of cancer in patients treated with immunosup-
pressive drugs. Br Med J 1979; 2: 1461–1466.
17. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on
dialysis and after renal transplantation. Lancet 2000; 355: 1886–
1887.
18. Blohme I, Brynger H. Malignant disease in renal transplant pa-
tients. Transplantation 1985; 39: 23–25.
19. Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, Conlon PJ, Mur-
phy GM. A population-based study of skin cancer incidence and
prevalence in renal transplant recipients. Br J Dermatol 2006; 154:
498–504.
20. Chapman J, Webster AC. Chapter 10. Cancer Report. In. Cancer
Report: ANZDATA Registry 2004 report. Adelaide, Australia: Aus-
tralia and New Zealand Dialysis and Transplant Registry, 2004.
21. Kyllonen L, Pukkala E, Eklund B. Cancer incidence in a kidney-
transplanted population. Transpl Int 1994; 7(Suppl 1): S350–
352.
22. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stew-
art JH, Law M et al. Cancer incidence before and after kidney
transplantation. JAMA 2006; 296: 2823–2831.
23. CIHI. Treatment of End-Stage Organ Failure in Canada, 2002 and
2003. Ottawa: CIHI 2005.
24. Copleston P, Fenton S, Kjellstrand C et al. The Canadian Organ
Replacement Register. Health Rep 1994; 6: 457–468.
25. Statistics Canada. Vital Statistics Death Database. [Inter-
net] 2006 September 2006 [cited 2006; Available at: www.
statcan.ca/english/sdds/3233.htm.
26. Schnatter AR, Acquavella JF, Thompson FS, Donaleski D, Theri-
ault G. An analysis of death ascertainment and follow-up through
statistics Canada’s Mortality Data Base system. Can J Public
Health 1990; 81: 60–65.
27. Goldberg MS, Carpenter M, Theriault G, Fair M. The accuracy of
ascertaining vital status in a historical cohort study of synthetic
textiles workers using computerized record linkage to the Cana-
dian Mortality Data Base. Can J Public Health 1993; 84: 201–
204.
28. Band PR, Gaudette LA, Hill GB et al. The Making of the Canadian
Cancer Registry: Cancer Incidence in Canada and Its Regions,
American Journal of Transplantation 2007; 7: 941–948 947
Villeneuve et al.
1969 to 1988. Ottawa: Ministry of Supply and Services Canada.
1993.
29. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer
Incidence in Five Continents. Lyon, France: International Agency
for Research on Cancer, 1997.
30. Preston DL, Lubin JH, Pierce DA, McConney M. EPICURE: Risk
regression and Data Analysis Software. Seattle: Hirosoft Interna-
tional Corporation, 1996.
31. Breslow NE, Day NE. Statistical methods in cancer research. Vol-
ume 2 - The design and analysis of cohort studies. IARC scientific
publiaction #82. Lyon: IARC 1987.
32. Southern DA, Faris PD, Brant R et al. Kaplan-Meier methods
yielded misleading results in competing risk scenarios. J Clin Epi-
demiol 2006; 59: 1110–1114.
33. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of
failure probabilities in the presence of competing risks: New rep-
resentations of old estimators. Stat Med 1999; 18: 695–706.
34. Naldi L, Fortina AB, Lovati S et al. Risk of nonmelanoma skin can-
cer in Italian organ transplant recipients. A registry-based study.
Transplantation 2000; 70: 1479–1484.
35. Serraino D, Piselli P, Angeletti C et al. Risk of Kaposi’s sarcoma and
of other cancers in Italian renal transplant patients. Br J Cancer
2005; 92: 572–575.
36. Rothman KJ. Moden Epidemiology. Boston: Little, Brown and
Company, 1986.
37. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol-
ume 2: The Design and Analysis of Cohort Studies. Lyon, France:
IARC, 1987.
38. Penn I. The changing pattern of posttransplant malignancies.
Transplant Proc 1991; 23: 1101–1103.
39. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for
the outpatient surveillance of renal transplant recipients. American
Society of Transplantation. J Am Soc Nephrol 2000; 11(Suppl 15):
S1–S86.
948 American Journal of Transplantation 2007; 7: 941–948
